Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Consensus and Guidelines · January 06, 2025

Use of Additional Doses of 2024–2025 COVID-19 Vaccine in Adults Aged ≥65 Years and Persons Aged ≥6 Months With Moderate or Severe Immunocompromise

MMWR. Morbidity and Mortality Weekly Report

 

Additional Info

Disclosure statements are available on the authors' profiles:

MMWR. Morbidity and Mortality Weekly Report
Use of Additional Doses of 2024-2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024
MMWR Morb. Mortal. Wkly. Rep. 2024 Dec 12;73(49)1118-1123, LE Roper, M Godfrey, R Link-Gelles, et al

Further Reading